{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:10:33Z","timestamp":1764238233050},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2023,5,1]]},"DOI":"10.1248\/bpb.b22-00670","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T22:13:38Z","timestamp":1682892818000},"page":"655-660","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of Appendicitis Cases in the Japanese Adverse Drug Event Report (JADER) Database"],"prefix":"10.1248","volume":"46","author":[{"given":"Yoji","family":"Kyotani","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Nara Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Nara Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiichi","family":"Nakahira","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Nara Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Yoshizumi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Nara Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ferris M, Quan S, Kaplan BS, Molodecky N, Ball CG, Chernoff GW, Bhala N, Ghosh S, Dixon E, Ng S, Kaplan GG. The global incidence of appendicitis: a systematic review of population-based studies. <i>Ann. Surg.<\/i>, <b>266<\/b>, 237\u2013241 (2017).","DOI":"10.1097\/SLA.0000000000002188"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Bhangu A, S\u00f8reide K, Di Saverio S, Assarsson JH, Drake FT. Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management. <i>Lancet<\/i>, <b>386<\/b>, 1278\u20131287 (2015).","DOI":"10.1016\/S0140-6736(15)00275-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Moris D, Paulson EK, Pappas TN. Diagnosis and management of acute appendicitis in adults: a review. <i>JAMA<\/i>, <b>326<\/b>, 2299\u20132311 (2021).","DOI":"10.1001\/jama.2021.20502"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lamps LW. Infectious causes of appendicitis. <i>Infect. Dis. Clin. North Am.<\/i>, <b>24<\/b>, 995\u20131018, ix\u2013x (2010).","DOI":"10.1016\/j.idc.2010.07.012"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Livingston EH, Woodward WA, Sarosi GA, Haley RW. Disconnect between incidence of nonperforated and perforated appendicitis: implications for pathophysiology and management. <i>Ann. Surg.<\/i>, <b>245<\/b>, 886\u2013892 (2007).","DOI":"10.1097\/01.sla.0000256391.05233.aa"},{"key":"6","unstructured":"6) CIOMS Working Group VIII. Practical aspects of signal detection in pharmacovigilance. CIOMS 2010."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sasaoka S, Matsui T, Hane Y, Abe J, Ueda N, Motooka Y, Hatahira H, Fukuda A, Naganuma M, Hasegawa S, Kinosada Y, Nakamura M. Time-to-onset analysis of drug-induced long QT syndrome based on a spontaneous reporting system for adverse drug events. <i>PLOS ONE<\/i>, <b>11<\/b>, e0164309 (2016).","DOI":"10.1371\/journal.pone.0164309"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>29<\/b>, 1279\u20131294 (2020).","DOI":"10.1002\/pds.5108"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Cornelius VR, Sauzet O, Evans SJW. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. <i>Drug Saf.<\/i>, <b>35<\/b>, 599\u2013610 (2012).","DOI":"10.2165\/11599740-000000000-00000"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. <i>J. Clin. Epidemiol.<\/i>, <b>49<\/b>, 1373\u20131379 (1996).","DOI":"10.1016\/S0895-4356(96)00236-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. <i>Am. J. Epidemiol.<\/i>, <b>165<\/b>, 710\u2013718 (2007).","DOI":"10.1093\/aje\/kwk052"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) H\u00e4rmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>64<\/b>, 743\u2013752 (2008).","DOI":"10.1007\/s00228-008-0475-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. <i>Drug Saf.<\/i>, <b>29<\/b>, 385\u2013396 (2006).","DOI":"10.2165\/00002018-200629050-00003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) In\u00e1cio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. <i>Br. J. Clin. Pharmacol.<\/i>, <b>83<\/b>, 227\u2013246 (2017).","DOI":"10.1111\/bcp.13098"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Akinola S, da Silveira CG, Corbin S, Lavall\u00e9e M, Thibault M, Gonella J, Gimenes FRE, Leclerc J. Using data from the Canadian post-marketing spontaneous pharmacovigilance system for drug safety research: a feasibility study. <i>Pharmaceut. Med.<\/i>, <b>34<\/b>, 263\u2013269 (2020).","DOI":"10.1007\/s40290-020-00345-w"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Dal Pan GJ, Lindquist M, Gelperin K. Postmarketing spontaneous pharmacovigilance reporting systems. <i>Textbook of pharmacoepidemiology<\/i>. (Strom BL ed.) John Wiley &amp; Sons, Chichester, pp. 99\u2013117 (2013).","DOI":"10.1002\/9781118344828.ch07"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. <i>Br. J. Clin. Pharmacol.<\/i>, <b>72<\/b>, 905\u2013908 (2011).","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Grover S, Hazari N, Chakrabarti S, Avasthi A. Relationship of obsessive compulsive symptoms\/disorder with clozapine: a retrospective study from a multispeciality tertiary care centre. <i>Asian J. Psychiatr.<\/i>, <b>15<\/b>, 56\u201361 (2015).","DOI":"10.1016\/j.ajp.2015.05.002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. <i>Am. J. Med.<\/i>, <b>111<\/b>, 716\u2013723 (2001).","DOI":"10.1016\/S0002-9343(01)01000-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Delgado A, Velosa J, Zhang J, Dursun SM, Kapczinski F, de Azevedo Cardoso T. Clozapine in bipolar disorder: a systematic review and meta-analysis. <i>J. Psychiatr. Res.<\/i>, <b>125<\/b>, 21\u201327 (2020).","DOI":"10.1016\/j.jpsychires.2020.02.026"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Bishara D, Taylor D. Adverse effects of clozapine in older patients: epidemiology, prevention, and management. <i>Drugs Aging<\/i>, <b>31<\/b>, 11\u201320 (2014).","DOI":"10.1007\/s40266-013-0144-2"},{"key":"22","unstructured":"22) Miller DD. Review and management of clozapine side effects. <i>J. Clin. Psychiatry<\/i>, <b>61<\/b> (Suppl. 8), 14\u201317, discussion, 18\u201319 (2000)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, MacCabe JH, Lally J. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. <i>Int. J. Mol. Sci.<\/i>, <b>17<\/b>, 863 (2016).","DOI":"10.3390\/ijms17060863"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. <i>J. Clin. Psychiatry<\/i>, <b>69<\/b>, 759\u2013768 (2008).","DOI":"10.4088\/JCP.v69n0509"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hussain ZH, Whitehead DA, Lacy BE. Fecal impaction. <i>Curr. Gastroenterol. Rep.<\/i>, <b>16<\/b>, 404 (2014).","DOI":"10.1007\/s11894-014-0404-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. <i>CNS Drugs<\/i>, <b>33<\/b>, 81\u201391 (2019).","DOI":"10.1007\/s40263-018-0587-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal \u2018slow gut\u2019 reactions, and comparison with international drug safety advice. <i>CNS Drugs<\/i>, <b>31<\/b>, 699\u2013709 (2017).","DOI":"10.1007\/s40263-017-0448-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Steinert T, Jans F. Six cases of perforated appendicitis during clozapine treatment. <i>J. Clin. Psychiatry<\/i>, <b>82<\/b>, 20cr13841 (2021).","DOI":"10.4088\/JCP.20cr13841"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y. Reintroduction of clozapine after perforation of the large intestine\u2014a case report and review of the literature. <i>Ann. Pharmacother.<\/i>, <b>47<\/b>, e31 (2013).","DOI":"10.1345\/aph.1S117"},{"key":"30","unstructured":"30) Misawa F, Nakajima N, Fujii Y, Takeuchi H. Clozapine and appendicitis: analyses based on a spontaneous reporting system database in Japan. <i>SSRN<\/i> (2022)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies. <i>Behav. Brain Res.<\/i>, <b>404<\/b>, 113168 (2021).","DOI":"10.1016\/j.bbr.2021.113168"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kawakita Y, Takeshima M, Komatsu T, Imanishi A, Fujiwara D, Itoh Y, Mishima K. Relationship between clozapine exposure and the onset of appendicitis in schizophrenia patients: a retrospective cohort study. <i>BMC Psychiatry<\/i>, <b>22<\/b>, 653 (2022).","DOI":"10.1186\/s12888-022-04312-4"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33) Maruya Y, Taniguchi K, Koga N, Azuma T, Matsuo S, Hayashi T, Eguchi S. Acute appendicitis in a rheumatoid arthritis patient treated with tocilizumab: report of a case. <i>Acta Med. Nagasaki.<\/i>, <b>60<\/b>, 29\u201331 (2015). doi.10.11343\/amn.60.29","DOI":"10.11343\/amn.60.29"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A. Tocilizumab monotherapy <i>versus<\/i> adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet<\/i>, <b>381<\/b>, 1541\u20131550 (2013).","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ramai D, Mozell D, Facciorusso A, Kewalramani A, Chandan S, Dhindsa B, Dhaliwal A, Khan S, Adler DG. Medications and the risk of perforated appendicitis: an adverse event report system (FAERS) database analysis. <i>Expert Rev. Gastroenterol. Hepatol.<\/i>, <b>16<\/b>, 1011\u20131017 (2022).","DOI":"10.1080\/17474124.2022.2143346"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. <i>Drug Des. Devel. Ther.<\/i>, <b>9<\/b>, 3031\u20133041 (2015).","DOI":"10.2147\/DDDT.S81998"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/5\/46_b22-00670\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T03:23:07Z","timestamp":1683343387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/5\/46_b22-00670\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00670","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"article-number":"b22-00670"}}